Drug major Ranbaxy Laboratories has received US health regulator's approval to market generic version of Novartis' Diovan tablets, used for treating high blood pressure and heart failure, in the US......
The long-awaited US approval for Ranbaxy Laboratories' generic version of anti-hypertension drug Diovan is likely to come this week, according to industry sources.While this could pull the company......
Ranbaxy Laboratories Ltd might lose the 180-day opportunity to exclusively sell its generic version of Novartis AG's hypertension drug Diovan if a US district court rules in favour of Mylan, which......
After its Paonta Sahib and Dewas units, Ranbaxy’s third and newly commissioned Mohali facility, too, appears to have come under the US regulator’s scanner. After finding deviations from......
The weakness in the stock was because of inspections by the American drug regulator at its Halol plant in Gujarat which resulted in eight observations, as well as a downward revision of speciality......